Integer Holdings Corp Dossier
Qualitative Analysis
Business overview
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world. The company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its primary brands include Greatbatch Medical and Lake Region Medical. Integer operates as a pure-play medical technology partner to major multi-national original equipment manufacturers (OEMs), providing end-to-end solutions from initial product design and development to full-scale commercial manufacturing. The company's product portfolio spans complex components, subassemblies, and finished devices used in interventional cardiology, structural heart, electrophysiology, and neurostimulation procedures.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Implementation of the standardized Integer Production System across global manufacturing facilities to drive operational excellence, enhance customer success, and improve leadership impact.
Expected impact: Aims to drive productivity gains, improve fixed cost absorption, and support the long-term target of achieving a 22% to 24% adjusted EBITDA margin.
Strategic focus on acquiring and integrating advanced, proprietary surface coating technologies (such as fluoropolymer, anodic, ion treatment, and parylene coatings) to enhance service offerings for complex medical devices.
Expected impact: Provides differentiated, high-value capabilities in cardio/vascular and CRM/neuromodulation segments, enabling faster product development and cross-selling pathways.
Construction and scaling of a new 67,000 square foot innovation and manufacturing center in Galway, Ireland, to expand regional R&D and manufacturing capacity.
Expected impact: Significantly increases capacity for high-demand neurovascular and structural heart products to support multinational OEM clients with localized European supply.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire a privately held manufacturer specializing in high-value surface coating technology platforms (fluoropolymer, anodic coatings, ion treatment, and laser processing) to expand Integer's proprietary coating capabilities.
Financial impact: Expected to contribute approximately $52 million in sales in 2025 with an accretive margin, offset by an expected $13 million NPV tax benefit.
To add advanced parylene coating technologies to Integer's portfolio, enhancing its capability to protect and improve the performance of complex implantable medical devices.
Financial impact: Expected to contribute approximately $7 million in sales in 2025 with an accretive margin, offset by an expected $3 million NPV tax benefit.